EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation

Semaglutid, Tirzepatid und klinisch erfasste alkoholbezogene Outcomes bei Typ-2-Diabetes: Target-Trial-Emulation

Huilin Tang iD, Bingyu Zhang iD, Ying Lu, Yiwen Lu, Haoyuan Wang, Christal N Davis, Henry R Kranzler, Yong Chen iD

Diabetes, Obesity and Metabolism · 03.11.2026

DOI: 10.1111/dom.71470 ↗

Auf einen Blick

Bei Erwachsenen mit Typ-2-Diabetes waren Semaglutid und Tirzepatid mit niedrigeren Raten klinisch erfasster AUD-assoziierter Hospitalisationen oder Notaufnahmen verbunden als SGLT2i. Zwischen Semaglutid und Tirzepatid zeigte sich kein Unterschied.

Fragestellung

Vergleicht das Risiko eines erstmals klinisch erfassten Alkoholgebrauchsstörungs-(AUD-)Outcomes unter Semaglutid, Tirzepatid oder SGLT2i bei Erwachsenen mit Typ-2-Diabetes?

Methode

Target-Trial-Emulation mit de-identifizierten EHR-Daten aus dem TriNetX-Netzwerk (Juni 2022 bis Januar 2025); 1:1 Propensity-Score-Matching; Cox-Modelle; Sensitivitäts- und Subgruppenanalysen.

Ergebnisse

Semaglutid vs. SGLT2i: 2,42 vs. 4,53 pro 1000 Personenjahre; HR 0,54 (95 %-KI 0,45–0,64). Tirzepatid vs. SGLT2i: 2,34 vs. 3,98; HR 0,61 (95 %-KI 0,46–0,83). Semaglutid vs. Tirzepatid: HR 0,98 (95 %-KI 0,73–1,31).

Schlussfolgerung der Autor:innen

Bei Erwachsenen mit Typ-2-Diabetes waren Semaglutid und Tirzepatid mit niedrigeren Raten klinisch erfasster AUD-assoziierter Outcomes verbunden als SGLT2i; zwischen beiden GLP-1RA bestand kein Unterschied.

Kernaussagen

  • Semaglutid vs. SGLT2i: HR 0,54 (95 %-KI 0,45–0,64)
  • Tirzepatid vs. SGLT2i: HR 0,61 (95 %-KI 0,46–0,83)
  • Semaglutid vs. Tirzepatid: kein Unterschied im Risiko

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.11.2026. Verfasst von Huilin Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Preventative Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philade…. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association, NIH HHS, National Institutes of Health.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the risk of incident alcohol use disorder (AUD) among adults with Type 2 diabetes (T2D) initiating semaglutide, tirzepatide or sodium‐glucose cotransporter‐2 inhibitors (SGLT2i). Materials and Methods We conducted a target trial emulation using de‐identified electronic health record data from the TriNetX research network (June 2022–January 2025). Adults with T2D newly initiating semaglutide, tirzepatide or an SGLT2i were included. The primary outcome was clinically recorded hospitalization or emergency department (ED) visits for AUD. Cox proportional hazards models with 1:1 propensity score matching (PSM) estimated hazard ratios (HRs) and 95% CIs. Sensitivity and subgroup analyses as well as secondary outcomes assessed the robustness of the findings.

Results

During a mean follow‐up of 0.81–1.02 years, the incidence rates (IRs) of clinically recorded hospitalization or ED visits for AUD were 2.42 versus 4.53 per 1000 person‐years for semaglutide versus SGLT2i, with an HR of 0.54 (95% CI, 0.45–0.64). Similarly, the IRs were 2.34 versus 3.98 per 1000 person‐years for tirzepatide versus SGLT2i, with an HR of 0.61 (95% CI, 0.46–0.83). In the direct comparison of semaglutide versus tirzepatide, IRs were 2.43 and 2.36 per 1000 person‐years, respectively, with no difference in risk (HR, 0.98; 95% CI, 0.73–1.31). Results were consistent across sensitivity and subgroup analyses and secondary outcomes.

Conclusions

In adults with T2D, semaglutide and tirzepatide were associated with lower rates of clinically recorded AUD‐related outcomes than SGLT2i, with no difference between the two GLP‐1RA medications.

Schlagwörter

Stichwörter der Autor:innen

GLP‐1 analogueSGLT2 inhibitorType 2 diabetespharmaco‐epidemiology

Autor:innen und Institutionen

  • Center for Preventative Ophthalmology and Biostatistics, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center and Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Penn Medicine Center for Evidence-Based Practice (CEP), University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Huilin Tang, Bingyu Zhang, Yong Chen

Förderung

  • American Heart Association
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Tang, H., Zhang, B., Lu, Y., Lu, Y., Wang, H., Davis, C. N., Kranzler, H. R., & Chen, Y. (2026). Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71470

Vancouver

Tang H, Zhang B, Lu Y, Lu Y, Wang H, Davis CN, et al. Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71470

BibTeX
@article{Tang2026,
  author = {Tang, Huilin and Zhang, Bingyu and Lu, Ying and Lu, Yiwen and Wang, Haoyuan and Davis, Christal N and Kranzler, Henry R and Chen, Yong},
  title = {Semaglutide, Tirzepatide and Clinically Recorded Alcohol‐Related Outcomes in Type 2 Diabetes: A Target Trial Emulation},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71470}
}
Kostenlos starten →